Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,464.46 46.78 0.32%
TOPIX 1,171.12 4.57 0.39%
HANG SENG 22,858.79 162.78 0.72%

Public Offerings, Merger Agreements, New Preclinical Data, New Treatments and Dividend Payments - Research Report on XOMA, MAKO,



Public Offerings, Merger Agreements, New Preclinical Data, New Treatments and
 Dividend Payments - Research Report on XOMA, MAKO, Alnylam, Avanir, and PDL
                                  BioPharma

PR Newswire

NEW YORK, December 18, 2013

NEW YORK, December 18, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting XOMA
Corporation (NASDAQ: XOMA), MAKO Surgical Corp. (NASDAQ: MAKO), Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY), Avanir Pharmaceuticals (NASDAQ: AVNR),
and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

XOMA Corporation Research Report

On December 13, 2013, XOMA Corp. (XOMA) announced the pricing of 9.5 million
shares of its common stock at a price to the public of $5.25 per share. The
Company reported that it has also granted the underwriters a 30-day option to
purchase up to an additional approximately 1.4 million shares of common stock
on the same terms and conditions. XOMA informed that after deducting the
underwriting discount and estimated offering expenses payable by the Company,
the aggregate net proceeds from the offering will amount to approximately
$46.5 million, which the Company intends to use for continued development,
preclinical testing and clinical studies related to gevokizumab and the XMet
platform, general research and development, business development and other
corporate purposes. The Company expects the offering to close on or about
December 18, 2013. The Full Research Report on XOMA Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/9a56_XOMA

MAKO Surgical Corp. Research Report

On December 13, 2013, MAKO Surgical Corp. (MAKO) announced the Mako
stockholders' approval of the adoption of the Agreement and Plan of Merger in
relation to the merger of MAKO with and into a wholly owned subsidiary of
Stryker Corporation. Under the terms of the Merger Agreement, MAKO
stockholders will receive $30 per share in cash at the closing of the merger.
The parties expect the transaction to close on December 17, 2013. The Full
Research Report on MAKO Surgical Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/7465_MAKO

Alnylam Pharmaceuticals, Inc. Research Report

On December 9, 2013, Alnylam Pharmaceuticals Inc. (Alnylam) announced the
presentation of new pre-clinical data with ALN-AT3 at the 55th Annual Meeting
of the American Society of Hematology (ASH) held December 7 - December 10,
2013 in New Orleans. Alnylam reported that ALN-AT3 is a subcutaneously
administered RNAi therapeutic targeting antithrombin (AT) for the treatment of
hemophilia and rare bleeding disorders (RBD). The studies demonstrated that
the repeat administration of ALN-AT3 was found to be well tolerated in
Hemophilia A (HA) mice, with no adverse findings up to dose levels 200 times
greater than levels required to achieve 50% AT knockdown. According to the
Company, the ALN-AT3 administration also demonstrated complete correction of
the activated Partial Thromboplastin Time (aPTT) - an ex vivo measure of blood
coagulation that is significantly prolonged in hemophilia - in HA mice. Akshay
Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of
Alnylam, commented, "These new data presented at ASH demonstrate that repeat
administration of ALN-AT3 is well tolerated in animal models of hemophilia,
and suggest that our RNAi therapeutic has the potential for a wide therapeutic
index in subjects with hemophilia. With MHRA approval of our recently filed
CTA, we look forward to the advancement of ALN-AT3 in our Phase I clinical
trial that we expect to start in early 2014, with data from hemophilia
subjects expected by the end of next year." The Full Research Report on
Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5b29_ALNY

Avanir Pharmaceuticals Research Report

On December 10, 2013, Avanir Pharmaceuticals (Avanir) reported its Q4 FY 2013
financial results (period ended September 30, 2013). The Company reported
total net revenues of $21.7 million, compared with $13.5 million in Q4 FY
2012. Net loss totaled $15.4 million or $0.10 per diluted share, compared with
a net loss of $11.7 million or $0.09 per diluted share in Q4 FY 2012. For
fiscal 2013, total net revenues were $75.4 million, 82.6% YoY growth. Net loss
for full-year 2013, was $55.5 million or $0.39 per diluted share, compared
with a net loss of $59.7 million or $0.45 per diluted share in full-year 2012.
Keith A. Katkin, President and CEO of Avanir commented, "We have achieved a
number of important and transformational milestones. In addition to robust
growth of NUEDEXTA for PBA, we formed a co-promote partnership with Merck
which will leverage our commercial leadership in the institutional setting. We
also in-licensed a new investigational migraine treatment, gained European
approval for NUEDEXTA and initiated a new phase II study of AVP-923 exploring
its potential application in levadopa-induced dyskinesias in Parkinson's
disease." The Full Research Report on Avanir Pharmaceuticals - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/2ee8_AVNR

PDL BioPharma, Inc. Research Report

On December 12, 2013, PDL BioPharma, Inc. (PDL BioPharma) announced the
completion of its regular quarterly dividend payment. The Company has
successfully paid the December 12, 2013 dividend payment of $0.15 per share to
all stockholders owning shares as of December 5, 2013, the record date. The
Full Research Report on PDL BioPharma, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/066b_PDLI

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement